arrow
T

Thomas E. Pennington

Melanoma Institute Australia
H指数:13
被引数:1,392

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictors of Immediate Therapeutic Lymph Node Dissection Instead of Index Lymph Node After Neoadjuvant Checkpoint Inhibitors: Lessons Learned from the PRADO Trial

新辅助免疫检查点抑制剂治疗后立即进行非原发淋巴结清扫的预测因素:PRADO试验的经验教训

2026-10-240
PRE
Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma.

在临床上可检测的III期黑色素瘤中,新辅助免疫治疗后,通过减少肿瘤床检查,病理反应计算评估仍然准确。

2025-11-010
PRE
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

III期黑色素瘤辅助治疗中的动态复发风险预测工具

2025-09-120
PRE
Nodal radioactivity after lymphoscintigraphy as a guide to sentinel node–positivity in melanoma patients

淋巴闪烁显像后的结节放射性作为黑色素瘤患者哨兵淋巴结阳性的指导

2025-06-090
OA
Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort

纵向分析揭示了在III期BRAF突变黑色素瘤队列中,对新辅助治疗有应答者的组织病理学特征发生动态变化。

2025-05-100
PRE
Cartilage Resection in the Surgical Management of Ear Melanoma

耳黑色素瘤手术管理中的软骨切除术

2025-04-280
OA
Patient and Staff Experiences of Embedding Electronic Patient Reported Outcome Measures for Distress Screening and Quality of Life Assessment, Into Routine Melanoma Care: A Mixed-Methods Study
2024-12-180
PRE
Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

帕博利珠单抗、达拉非尼和曲美替尼治疗BRAFV600-mutant可切除黑色素瘤的新辅助治疗: 随机2期NeoTrio试验

2024-06-213
OAAI
The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort

新辅助系统治疗对III期黑色素瘤淋巴结清扫术后手术结果的影响; 澳大利亚队列

2024-05-181
OAAI
ASO Visual Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort
2024-05-170
PRE
ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging
2023-12-200
PRE
Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging
2023-11-154
OAAI
Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
2023-10-011
OA